Cboe UK DKK

ALK-Abelló A/S (ALKBC.XC)

146.60

0.00

(0.00%)

At close: April 24 at 12:01:25 PM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ALKBC.XC

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

ACARIZAX® approved in Canada for treatment of young children

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance